drugset / Trial / NCT01874535

Rate of Complete Symptom Relief, Prevention of Symptom Relapse: Grades A and B Esophagitis of Esomeprazole Therapy

NCT01874535

Phase 4 Completed 408 enrolled Chang Gung Memorial Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

To investigate the impact of initial treatment duration (4-week versus 8-week)of Esomeprazole (40mg) on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis

Timeline

Start
2010-06
Primary completion
2016-06
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Esomeprazole Small molecule 40 mg

Indications